The incretin system ABCs in obesity and diabetes - novel therapeutic strategies for weight loss and beyond

Obesity Reviews

Volumn 17, Issue 7, 2016, Pages 553-572

  Joao A L ^a   Reis, F ^a   Fernandes, R ^a  

^a UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Bariatric surgery; Incretins; Obesity; Type 2 diabetes mellitus (T2DM)

Indexed keywords

BILE ACID; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GHRELIN; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INCRETIN; LEPTIN; DPP4 PROTEIN, HUMAN; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INSULIN;

ARTICLE; BARIATRIC SURGERY; HOMEOSTASIS; HUMAN; INFLAMMATION; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOGENESIS; WEIGHT REDUCTION; ANIMAL; BLOOD; DIABETES MELLITUS, TYPE 2; DISEASE MODEL; METABOLISM; SECRETION (PROCESS);

ANIMALS; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; DISEASE MODELS, ANIMAL; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; INCRETINS; INSULIN; OBESITY; WEIGHT LOSS;

EID: 84964599874     PISSN: 14677881     EISSN: 1467789X     Source Type: Journal    
DOI: 10.1111/obr.12421     Document Type: Article

References (151)

1. World Health Organization (WHO). Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000; 894: 1-253.
2. Kaur J. A comprehensive review on metabolic syndrome. Cardiol Res Pract 2014; 2014: 943162.
3. International Diabetes Federation. IDF Diabetes Atlas Seventh Edition. 2015.
4. Virally M, Blicklé J-F, Girard J, Halimi S, Simon D, Guillausseau P-J. Type 2 diabetes mellitus: epidemiology, pathophysiology, unmet needs and therapeutical perspectives. Diabetes Metab 2007; 33: 231-44.
5. Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 2004; 287: E199-206.
6. Drucker DJ. The biology of incretin hormones. Cell Metab 2006; 3: 153-65.
7. Cernea S. The role of incretin therapy at different stages of diabetes. Rev Diabet Stud 2011; 8: 323-38.
8. Godinho R, Mega C, Teixeira-de-lemos E et al. The place of dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapeutics: a 'me too' or ' the special one' antidiabetic class? J Diabetes Res 2015; 2015: 806979.
9. Avogaro A, Fadini GP. The effects of dipeptidyl peptidase-4 inhibition on microvascular diabetes complications. Diabetes Care 2014; 37: 2884-94.
10. Seino Y, Yabe D. Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas. J Diabetes Investig 2013; 4: 108-30.
11. Muscelli E, Mari A, Casolaro A et al. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes 2008; 57: 1340-8.
12. Torekov SS, Madsbad S, Holst JJ. Obesity - an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential. Obes Rev 2011; 12: 593-601.
13. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-705.
14. Wilding JP. The importance of weight management in type 2 diabetes mellitus. Int J Clin Pract 2014; 68: 682-91.
15. Laferrère B. Diabetes remission after bariatric surgery: is it just the incretins? Int J Obes 2011; 35: S22-5.
16. Schauer PR, Kashyap SR, Wolski K et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 2012; 366: 1567-76.
17. Mingrone G, Panunzi S, De Gaetano A et al. Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5year follow-up of an open-label, single-centre, randomised controlled trial. Lancet 2015; 386: 964-73.
18. Park CW, Torquati A. Physiology of weight loss surgery. Surg Clin North Am 2011; 91: 1149-61, vii.
19. Wilcox G. Insulin and insulin resistance. Clin Biochem Ver 2005; 26: 19-39.
20. Polonsky KS, Burant CF. Chapter 31 - type 2 diabetes mellitus. In: Williams Textbook of Endocrinology, 13th edn. Elsevier Inc: Philadelphia, United states, 2016, pp. 1385-450.
21. Romeo GR, Lee J, Shoelson SE. Metabolic syndrome, insulin resistance, and roles of inflammation - mechanisms and therapeutic targets. Arterioscler Thromb Vasc Biol 2012; 32: 1771-6.
22. Aroor A, McKarns S, Nistala R, Demarco V et al. DPP-4 Inhibitors as therapeutic modulators of immune cell function and associated cardiovascular and renal insulin resistance in obesity and diabetes. Cardiorenal Med 2013; 3: 48-56.
23. Stienstra R, van Diepen JA, Tack CJ et al. Inflammasome is a central player in the induction of obesity and insulin resistance. Proc Natl Acad Sci U S A 2011; 108: 15324-9.
24. Creutzfeldt W. The [pre-] history of the incretin concept. Regul Pept 2005; 128: 87-91.
25. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132: 2131-57.
26. Seino Y, Fukushima M, Yabe D. GIP and GLP-1, the two incretin hormones: similarities and differences. J Diabetes Investig 2010; 1: 8-23.
27. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007; 87: 1409-39.
28. Oyama J-I, Higashi Y, Node K. Do incretins improve endothelial function? Cardiovasc Diabetol 2014; 13: 21.
29. Panchapakesan U, Mather A, Pollock C. Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease. Clin Sci 2013; 124: 17-26.
30. Gorrell MD, Gysbers V, McCaughan GW. CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes. Scand J Immunol 2001; 54: 249-64.
31. Mentlein R. Mechanisms underlying the rapid degradation and elimination of the incretin hormones GLP-1 and GIP. Best Pract Res Clin Endocrinol Metab 2009; 23: 443-52.
32. Idorn T, Knop FK, Jørgensen MB et al. Elimination and degradation of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with end-stage renal disease. J Clin Endocrinol Metab 2014; 99: 2457-66.
33. Zhong J, Gong Q, Goud A, Srinivasamaharaj S, Rajagopalan S. Recent advances in dipeptidyl-peptidase-4 inhibition therapy: lessons from the bench and clinical trials. J Diabetes Res 2015; 2015: 606031.
34. Nistala R, Habibi J, Lastra G et al. Prevention of obesity-induced renal injury in male mice by DPP4 inhibition. Endocrinology 2014; 155: 2266-76.
35. Lamers D, Famulla S, Wronkowitz N et al. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes 2011; 60: 1917-25.
36. O'Leary H, Ou X, Broxmeyer HE. The role of dipeptidyl peptidase 4 in hematopoiesis and transplantation. Curr Opin Hematol 2013; 20: 314-9.
37. Mulvihill EE, Drucker DJ. Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocr Rev 2014; 35: 992-1019.
38. Haskó G, Cronstein BN. Adenosine: an endogenous regulator of innate immunity. Trends Immunol 2004; 25: 33-9.
39. Knop FK, Vilsbøll T, Højberg PV et al. Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state? Diabetes 2007; 56: 1951-9.
40. Holst JJ. Glucagon-like peptide-1, a gastrointestinal hormone with a pharmaceutical potential. Curr Med Chem 1999; 6: 1005-17.
41. Gerich JE. Is reduced first-phase insulin release the earliest detectable abnormality in individuals destined to develop type 2 diabetes? Diabetes 2002; 51: S117-21.
42. Woerle HJ, Carneiro L, Derani A, Göke B, Schirra J. The role of endogenous incretin secretion as amplifier of glucose-stimulated insulin secretion in healthy subjects and patients with type 2 diabetes. Diabetes 2012; 61: 2349-58.
43. McKillop AM, Duffy NA, Lindsay JR, O'Harte FPM, Bell PM, Flatt PR. Decreased dipeptidyl peptidase-IV activity and glucagon-like peptide-1(7-36)amide degradation in type 2 diabetic subjects. Diabetes Res Clin Pract 2008; 79: 79-85.
44. Meneilly GS, Demuth HU, McIntosh CH, Pederson RA. Effect of ageing and diabetes on glucose-dependent insulinotropic polypeptide and dipeptidyl peptidase IV responses to oral glucose. Diabet Med 2000; 17: 346-50.
45. Mannucci E, Pala L, Ciani S et al. Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus. Diabetologia 2005; 48: 1168-72.
46. Marques C, Mega C, Gonçalves A et al. Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animals. Mediators Inflamm 2014; 2014: 538737.
47. Pala L, Mannucci E, Pezzatini A et al. Dipeptidyl peptidase-IV expression and activity in human glomerular endothelial cells. Biochem Biophys Res Commun 2003; 310: 28-31.
48. Mega C, Vala H, Rodrigues-Santos P et al. Sitagliptin prevents aggravation of endocrine and exocrine pancreatic damage in the Zucker Diabetic Fatty rat - focus on amelioration of metabolic profile and tissue cytoprotective properties. Diabetol Metab Syndr 2014; 6: 42.
49. Derosa G, Franzetti IG, Querci F et al. Exenatide plus metformin compared with metformin alone on β-cell function in patients with type 2 diabetes. Diabet Med 2012; 29: 1515-23.
50. George RE, Joseph S. A review of newer treatment approaches for type-2 diabetes: focusing safety and efficacy of incretin based therapy. Saudi Pharm J 2014; 22: 403-10.
51. Ceriello A, Novials A, Ortega E et al. Glucagon-like peptide 1 reduces endothelial dysfunction, inflammation, and oxidative stress induced by both hyperglycemia and hypoglycemia in type 1 diabetes. Diabetes Care 2013; 36: 2346-50.
52. Ferreira L, Teixeira-De-Lemos E, Pinto F et al. Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat). Mediators Inflamm 2010; 2010: 592760.
53. Mega C, Teixeira De Lemos E, Vala H et al. Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat). Exp Diabetes Res 2011; 2011: 162092.
54. Gonçalves A, Leal E, Paiva A et al. Protective effects of the dipeptidyl peptidase IV inhibitor sitagliptin in the blood-retinal barrier in a type 2 diabetes animal model. Diabetes Obes Metab 2012; 14: 454-63.
55. Gonçalves A, Marques C, Leal E et al. Dipeptidyl peptidase-IV inhibition prevents blood-retinal barrier breakdown, inflammation and neuronal cell death in the retina of type 1 diabetic rats. Biochim Biophys Acta 2014; 1842: 1454-63.
56. Huda MSB, Wilding JPH, Pinkney JH. Gut peptides and the regulation of appetite. Obes Rev 2006; 7: 163-82.
57. Ranganath L, Norris F, Morgan L, Wright J, Marks V. Inhibition of carbohydrate-mediated glucagon-like peptide-1 (7-36)amide secretion by circulating non-esterified fatty acids. Clin Sci (Lond) 1999; 96: 335-42.
58. Bojanowska E. Physiology and pathophysiology of glucagon-like peptide-1 (GLP-1): the role of GLP-1 in the pathogenesis of diabetes mellitus, obesity, and stress. Med Sci Monit 2005; 11: RA271-8.
59. Zhou J, Roane DS, Xi X, Bogacka I et al. Short-term food restriction and refeeding alter expression of genes likely involved in brain glucosensing. Exp Biol Med (Maywood) 2003; 228: 943-50.
60. Näslund E, Barkeling B, King N et al. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab Disord 1999; 23: 304-11.
61. Iwase M, Yamamoto M, Iino K et al. Obesity induced by neonatal monosodium glutamate treatment in spontaneously hypertensive rats: an animal model of multiple risk factors. Hypertens Res 1998; 21: 1-6.
62. Tang-Christensen M, Vrang N, Larsen PJ. Glucagon-like peptide 1(7-36) amide's central inhibition of feeding and peripheral inhibition of drinking are abolished by neonatal monosodium glutamate treatment. Diabetes 1998; 47: 530-7.
63. Boonnate P, Waraasawapati S, Hipkaeo W et al. Monosodium glutamate dietary consumption decreases pancreatic β-cell mass in adult Wistar rats. PLoS One 2015; 10: e0131595.
64. Heppner KM, Perez-Tilve D. GLP-1 based therapeutics: simultaneously combating T2DM and obesity. Front Neurosci 2015; 9: 92.
65. Skibicka KP. The central GLP-1: implications for food and drug reward. Front Neurosci 2013; 7: 181.
66. Tong J, Sandoval DA. Is the GLP-1 system a viable therapeutic target for weight reduction? Rev Endocr Metab Disord 2011; 12: 187-95.
67. van Can J, Sloth B, Jensen CB, Flint A, Blaak EE, Saris WHM. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes 2014; 38: 784-93.
68. Sandoval D. CNS GLP-1 regulation of peripheral glucose homeostasis. Physiol Behav 2008; 94: 670-4.
69. Kastin AJ, Akerstrom V, Pan W. Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J Mol Neurosci 2002; 18: 7-14.
70. Orskov C, Puolsen S, Moller M, Holst JJ. Glucagon-like peptide 1 receptors in the subformical organ and the area postrema are accessible to circulating glucagon-like peptide 1. Diabetes 1996; 45: 832-5.
71. Gross PM, Wall KM, Pang JJ, Shaver SW, Wainman DS. Microvascular specializations promoting rapid interstitial solute dispersion in nucleus tractus solitarius. Am J Physiol 1990; 259: R1131-8.
72. Göke R, Larsen PJ, Mikkelsen JD, Sheikh SP. Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur J Neurosci 1995; 7: 2294-300.
73. Shah M, Vella A. Effects of GLP-1 on appetite and weight. Rev Endocr Metab Disord 2014; 15: 181-7.
74. Delgado-Aros S, Kim D-Y, Burton DD et al. Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans. Am J Physiol Gastrointest Liver Physiol 2002; 282: G424-31.
75. Iepsen EW, Torekov SS, Holst JJ. Therapies for inter-relating diabetes and obesity - GLP-1 and obesity. Expert Opin Pharmacother 2014; 15: 2487-500.
76. Klok MD, Jakobsdottir S, Drent ML. The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review. Obes Rev 2007; 8: 21-34.
77. Gagnon J, Baggio LL, Drucker DJ, Brubaker PL. Ghrelin is a novel regulator of GLP-1 secretion. Diabetes 2015; 64: 1513-21.
78. Ronveaux CC, Tomé D, Raybould HE. Glucagon-like peptide 1 interacts with ghrelin and leptin to regulate glucose metabolism and food intake through vagal afferent neuron signaling. J Nutr 2015; 145: 672-80.
79. Chelikani PK, Haver AC, Reidelberger RD. Ghrelin attenuates the inhibitory effects of glucagon-like peptide-1 and peptide YY(3-36) on food intake and gastric emptying in rats. Diabetes 2006; 55: 3038-46.
80. Clément K, Vaisse C, Lahlou N et al. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature 1998; 392: 398-401.
81. Rocca AS, Brubaker PL. Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion. Endocrinology 1999; 140: 1687-94.
82. Anini Y, Brubaker PL. Role of leptin in the regulation of glucagon-like peptide-1 secretion. Diabetes 2003; 52: 252-9.
83. Dong CX, Brubaker PL. Ghrelin, the proglucagon-derived peptides and peptide YY in nutrient homeostasis. Nat Rev Gastroenterol Hepatol 2012; 9: 705-15.
84. Gil-Lozano M, Mingomataj EL, Wu WK, Ridout SA, Brubaker PL. Circadian secretion of the intestinal hormone GLP-1 by the rodent L cell. Diabetes 2014; 63: 3674-85.
85. de Git KCG, Adan RAH. Leptin resistance in diet-induced obesity: the role of hypothalamic inflammation. Obes Rev 2015; 16: 207-24.
86. Troke RC, Tan TM, Bloom SR. The future role of gut hormones in the treatment of obesity. Ther Adv Chronic Dis 2014; 5: 4-14.
87. Frezza EE. Are we closer to finding the treatment for type 2 diabetes mellitus in morbid obesity? Are the incretins the key to success? Obes Surg 2004; 14: 999-1005.
88. Collins D, Hogan AM, O'Shea D, Winter DC. The Omentum: anatomical, metabolic, and surgical aspects. J Gastrointest Surg 2009; 13: 1138-46.
89. Cancello R, Tordjman J, Poitou C et al. Increased infiltration of macrophages in omental adipose tissue is associated with marked hepatic lesions in morbid human obesity. Diabetes 2006; 55: 1554-61.
90. Djiogue S, Kamdje AHN, Vecchio L et al. Insulin resistance and cancer: the role of insulin and IGFs. Endocr Relat Cancer 2013; 20: 1-17.
91. Moraes-Vieira PMM, Bassi EJ, Araujo RC, Câmara NO. Leptin as a link between the immune system and kidney-related diseases: leading actor or just a coadjuvant? Obes Rev 2012; 13: 733-43.
92. Tataranni PA, Ortega E. A burning question: does an adipokine-induced activation of the immune system mediate the effect of overnutrition on type 2 diabetes? Diabetes 2005; 54: 917-27.
93. Cancello R, Henegar C, Viguerie N et al. Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes 2005; 54: 2277-86.
94. Curat CA, Miranville A, Sengenès C et al. From blood monocytes to adipose tissue-resident macrophages: induction of diapedesis by human mature adipocytes. Diabetes 2004; 53: 1285-92.
95. Kintscher U, Hartge M, Hess K et al. T-lymphocyte infiltration in visceral adipose tissue: a primary event in adipose tissue inflammation and the development of obesity-mediated insulin resistance. Arterioscler Thromb Vasc Biol 2008; 28: 1304-10.
96. Zhong J, Rao X, Deiuliis J et al. A potential role for dendritic cell/macrophage-expressing DPP4 in obesity-induced visceral inflammation. Diabetes 2013; 62: 149-57.
97. Apostolopoulos V, de Courten MPJ, Stojanovska L, Blatch GL, Tangalakis K, de Courten B. The complex immunological and inflammatory network of adipose tissue in obesity. Mol Nutr Food Res 2016; 60: 43-57.
98. Hooper LV, Macpherson AJ. Immune adaptations that maintain homeostasis with the intestinal microbiota. Nat Rev Immunol 2010; 10: 159-69.
99. von Websky K, Reichetzeder C, Hocher B. Physiology and pathophysiology of incretins in the kidney. Curr Opin Nephrol Hypertens 2014; 23: 54-60.
100. Kos K, Baker AR, Jernas M et al. DPP-IV inhibition enhances the antilipolytic action of NPY in human adipose tissue. Diabetes Obes Metab 2009; 11: 285-92.
101. Patel D. Pharmacotherapy for the management of obesity. Metabolism 2015; 64: 1376-85.
102. SAXENDA (Liraglutide [rDNA Origin] Injection) Prescribing Information. Novo Nordisk Inc 2014.
103. Wadden TA, Hollander P, Klein S et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE maintenance randomized study. Int J Obes 2013; 37: 1443-51.
104. TM - Diabetes; ClinicalTrials.gov [Internet]. [cited 2016 Feb 9]. Available from: https://clinicaltrials.gov/ct2/show/NCT01272232
105. Pi-Sunyer X, Astrup A, Fujioka K et al. A randomized, controlled trial of 3.0mg of liraglutide in weight management. N Engl J Med 2015; 373: 11-22.
106. Xiao C, Dash S, Lewis GF. Mechanisms of incretin effects on plasma lipids and implications for the cardiovascular system. Cardiovasc Hematol Agents Med Chem 2012; 10: 289-94.
107. Katout M, Zhu H, Rutsky J et al. Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: results of a systematic meta-analysis and meta-regression. Am J Hypertens 2014; 27: 130-9.
108. Marathe CS, Rayner CK, Jones KL, Horowitz M. Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function. Exp Diabetes Res 2011; 2011: 279530.
109. Welzl H, D'Adamo P, Lipp HP. Conditioned taste aversion as a learning and memory paradigm. Behav Brain Res 2001; 125: 205-13.
110. St Onge EL, Miller SA. Albiglutide: a new GLP-1 analog for the treatment of type 2 diabetes. Expert Opin Biol Ther 2010; 10: 801-6.
111. Andrade S, Pinho F, Ribeiro AM et al. Immunization against active ghrelin using virus-like particles for obesity treatment. Curr Pharm Des 2013; 19: 6551-8.
112. de Mello AH, Prá M, Cardoso LC, de Bona Schraiber R, Rezin GT. Incretin-based therapies for obesity treatment. Metabolism 2015; 64: 967-81.
113. Shimasaki T, Masaki T, Mitsutomi K et al. The dipeptidyl peptidase-4 inhibitor des-fluoro-sitagliptin regulates brown adipose tissue uncoupling protein levels in mice with diet-induced obesity. PLoS One 2013; 8: e63626.
114. Lee P, Swarbrick MM, Ho KKY. Brown adipose tissue in adult humans: a metabolic renaissance. Endocr Rev 2013; 34: 413-38.
115. Fukuda-Tsuru S, Kakimoto T, Utsumi H, Kiuchi S, Ishii S. The novel dipeptidyl peptidase-4 inhibitor teneligliptin prevents high-fat diet-induced obesity accompanied with increased energy expenditure in mice. Eur J Pharmacol 2014; 723: 207-15.
116. Zhong J, Maiseyeu A, Davis SN, Rajagopalan S. DPP4 in cardiometabolic diseases - recent insights from the laboratory and clinical trials of DPP4 inhibition. Circ Res 2015; 116: 1491-504.
117. Marney A, Kunchakarra S, Byrne L, Brown NJ. Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans. Hypertension 2010; 56: 728-33.
118. Muskiet MHA, Smits MM, Morsink LM, Diamant M. The gut-renal axis: do incretin-based agents confer renoprotection in diabetes? Nat Rev Nephrol 2014; 10: 88-103.
119. Chaykovska L, Alter ML, von Websky K et al. Effects of telmisartan and linagliptin when used in combination on blood pressure and oxidative stress in rats with 2-kidney-1-clip hypertension. J Hypertens 2013; 31: 2290-8.
120. Kim D, Kim J, Yoon JH et al. CXCL12 secreted from adipose tissue recruits macrophages and induces insulin resistance in mice. Diabetologia 2014; 57: 1456-65.
121. Gallagher KA, Liu Z-J, Xiao M et al. Diabetic impairments in NO-mediated endothelial progenitor cell mobilization and homing are reversed by hyperoxia and SDF-1 alpha. J Clin Invest 2007; 117: 1249-59.
122. Fadini GP, Boscaro E, Albiero M et al. The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha. Diabetes Care 2010; 33: 1607-9.
123. Zaruba M-M, Theiss HD, Vallaster M et al. Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction. Cell Stem Cell 2009; 4: 313-23.
124. Stokman G, Stroo I, Claessen N, Teske GJD, Florquin S, Leemans JC. SDF-1 provides morphological and functional protection against renal ischaemia/reperfusion injury. Nephrol Dial Transplant 2010; 25: 3852-9.
125. Jungraithmayr W, De Meester I, Matheeussen V, Baerts L, Arni S, Weder W. CD26/DPP-4 inhibition recruits regenerative stem cells via stromal cell-derived factor-1 and beneficially influences ischaemia reperfusion injury in mouse lung transplantation. Eur J Cardio-thoracic Surg 2012; 41: 1166-73.
126. Hansen HH, Hansen G, Paulsen S et al. The DPP-IV inhibitor linagliptin and GLP-1 induce synergistic effects on body weight loss and appetite suppression in the diet-induced obese rat. Eur J Pharmacol 2014; 741: 254-63.
127. Lindekilde N, Gladstone BP, Lübeck M et al. The impact of bariatric surgery on quality of life: a systematic review and meta-analysis. Obes Rev 2015; 16: 639-51.
128. Kamvissi V, Salerno A, Bornstein SR, Mingrone G, Rubino F. Incretins or anti-incretins? A new model for the 'entero-pancreatic axis'. Horm Metab Res 2015; 47: 84-7.
129. Guedes TP, Martins S, Costa M et al. Detailed characterization of incretin cell distribution along the human small intestine. Surg Obes Relat Dis 2015; 11: 1323-31.
130. Eickhoff H, Louro TM, Matafome PN, Vasconcelos F, Seiça RM, Castro e Sousa F. Amelioration of glycemic control by sleeve gastrectomy and gastric bypass in a lean animal model of type 2 diabetes: restoration of gut hormone profile. Obes Surg 2015; 25: 7-18.
131. Habegger KM, Kirchner H, Yi C-X et al. GLP-1R agonism enhances adjustable gastric banding in diet-induced obese rats. Diabetes 2013; 62: 3261-7.
132. Aarts E, Koehestanie P, Dogan K, Berends F, Janssen I. Revisional surgery after failed gastric banding: results of one-stage conversion to RYGB in 195 patients. Surg Obes Relat Dis 2014; 10: 1077-83.
133. Iglesias P, Civantos S, Vega B, Pavón I, Guijarro G, Monereo S. Clinical effectiveness of exenatide in diabetic patients waiting for bariatric surgery. Obes Surg 2015; 25: 575-8.
134. Monte SV, Caruana JA, Ghanim H et al. Reduction in endotoxemia, oxidative and inflammatory stress, and insulin resistance after Roux-en-Y gastric bypass surgery in patients with morbid obesity and type 2 diabetes mellitus. Surgery 2012; 151: 587-93.
135. Zarrinpar A, Loomba R. Review article: the emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2012; 36: 909-21.
136. Pournaras DJ, Roux CW. Are bile acids the new gut hormones? Lessons from weight loss surgery models. Endocrinology 2013; 154: 2255-6.
137. Kohli R, Bradley D, Setchell KD, Eagon JC, Abumrad N, Klein S. Weight loss induced by Roux-en-Y gastric bypass but not laparoscopic adjustable gastric banding increases circulating bile acids. J Clin Endocrinol Metab 2013; 98: E708-12.
138. Scholtz S, Miras AD, Chhina N et al. Obese patients after gastric bypass surgery have lower brain-hedonic responses to food than after gastric banding. Gut 2014; 63: 891-902.
139. Münzberg H, Laque A, Yu S, Rezai-Zadeh K, Berthoud H-R. Appetite and body weight regulation after bariatric surgery. Obes Rev 2015; 16: 77-90.
140. Keitel V, Görg B, Bidmon HJ et al. The bile acid receptor TGR5 (Gpbar-1) acts as a neurosteroid receptor in brain. Glia 2010; 58: 1794-805.
141. Reiner Z, Catapano AL, De Backer G et al. ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32: 1769-818.
142. Out C, Groen AK, Brufau G. Bile acid sequestrants: more than simple resins. Curr Opin Lipidol 2012; 23: 43-55.
143. Potthoff MJ, Potts A, He T et al. Colesevelam suppresses hepatic glycogenolysis by TGR5-mediated induction of GLP-1 action in DIO mice. Am J Physiol Gastrointest Liver Physiol 2013; 304: G371-80.
144. Tseng C-H, Lee K-Y, Tseng F-H. An updated review on cancer risk associated with incretin mimetics and enhancers. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 2015; 33: 67-124.
145. Akaslan SB, Degertekin CK, Yilmaz G, Cakir N, Arslan M, Toruner FB. Effects of sitagliptin on nonalcoholic fatty liver disease in diet-induced obese rats. Metab Syndr Relat Disord 2013; 11: 243-50.
146. Ohyama T, Sato K, Yamazaki Y et al. MK-0626, a selective DPP-4 inhibitor, attenuates hepatic steatosis in ob/ob mice. World J Gastroenterol 2014; 20: 16227-35.
147. Apaijai N, Chinda K, Palee S, Chattipakorn S, Chattipakorn N. Combined vildagliptin and metformin exert better cardioprotection than monotherapy against ischemia-reperfusion injury in obese-insulin resistant rats. PLoS One 2014; 9: e102374.
148. Bostick B, Habibi J, Ma L et al. Dipeptidyl peptidase inhibition prevents diastolic dysfunction and reduces myocardial fibrosis in a mouse model of western diet induced obesity. Metabolism 2014; 63: 1000-11.
149. Huisamen B, Genis A, Marais E, Lochner A. Pre-treatment with a DPP-4 inhibitor is infarct sparing in hearts from obese, pre-diabetic rats. Cardiovasc Drugs Ther 2011; 25: 13-20.
150. Nistala R, Habibi J, Aroor A et al. DPP4 inhibition attenuates filtration barrier injury and oxidant stress in the Zucker obese rat. Obesity (Silver Spring) 2014; 22: 2172-9.
151. Omar BA, Vikman J, Winzell MS et al. Enhanced beta cell function and anti-inflammatory effect after chronic treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin in an advanced-aged diet-induced obesity mouse model. Diabetologia 2013; 56: 1752-60.